Quote this publication Share Print

MABTHERA

-
Opinions on drugs - Posted on Nov 08 2006

Reason for request

Inclusion on the list of medicines approved for use by hospitals in the extension of indication: MabThera® maintenance therapy is indicated for patients with relapsed or refractory follicular lymphoma responding to induction therapy with chemotherapy with or without MabThera®.

-


Clinical Benefit

Substantial

The actual benefit of MabThera® in the context of maintenance treatment for non-Hodgkin’s follicular lymphoma is substantial.


Clinical Added Value

major

In maintenance treatment for relapsed or refractory follicular lymphoma, MabThera® provides a major IAB (IAB I) in terms of efficacy compared with the current treatment strategy.


Contact Us

Évaluation des médicaments